Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 141, Issue 8, Pages 1237-1248Publisher
WILEY
DOI: 10.1038/sj.bjp.0705741
Keywords
colonic diseases; functional; treatment; challenges; opportunities
Categories
Funding
- NIDDK NIH HHS [R01 DK054681, DK 02638, K24 DK002638, R01 DK 54681] Funding Source: Medline
Ask authors/readers for more resources
This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available